Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04940052
Title Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | CAN | BRA | ARG

Facility Status City State Zip Country Details
Northwestern University Med School Chicago Illinois 60611 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Novartis Investigative Site Caba Buenos Aires C1417DTB Argentina Details
Novartis Investigative Site Rio De Janiero RJ 20231-050 Brazil Details
Novartis Investigative Site Blumenau Santa Catarina 89015-200 Brazil Details
Novartis Investigative Site Sao Paulo SP 01246-000 Brazil Details
Novartis Investigative Site Edmonton Alberta T6G 1Z2 Canada Details
Novartis Investigative Site London Ontario N6A 5W9 Canada Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Fuzhou Fujian 350014 China Details
Novartis Investigative Site Zhengzhou Henan 450008 China Details
Novartis Investigative Site Wuhan Hubei 430022 China Details
Novartis Investigative Site Changsha Hunan 410013 China Details
Novartis Investigative Site Nanjing Jiangsu 210006 China Details
Novartis Investigative Site Nanjing Jiangsu 210009 China Details
Novartis Investigative Site Xuzhou Jiangsu 221003 China Details
Novartis Investigative Site Changchun Jilin 130033 China Details
Novartis Investigative Site Xian Shanxi 710061 China Details
Novartis Investigative Site Chengdu Sichuan 610041 China Details
Novartis Investigative Site Tianjin Tianjin 300121 China Details
Novartis Investigative Site Beijing 100036 China Details
Novartis Investigative Site Beijing 100730 China Details
Novartis Investigative Site Guangzhou 510060 China Details
Novartis Investigative Site Shanghai 200233 China Details
Novartis Investigative Site Tianjin 300052 China Details
Novartis Investigative Site Tianjin 300480 China Details
Novartis Investigative Site Hisar Haryana 125005 India Details
Novartis Investigative Site Chennai 600 020 India Details
Novartis Investigative Site New Delhi 110029 India Details
Novartis Investigative Site Seoul Seocho Gu 06591 Korea, Republic of Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Seoul 05505 Korea, Republic of Details
Novartis Investigative Site Seoul 06351 Korea, Republic of Details
Novartis Investigative Site Kuching Sarawak 93586 Malaysia Details
Novartis Investigative Site Kuala Lumpur 59100 Malaysia Details
Novartis Investigative Site Pulau Pinang 10990 Malaysia Details
Novartis Investigative Site Tainan 70403 Taiwan Details
Novartis Investigative Site Taipei 10002 Taiwan Details
Novartis Investigative Site Istanbul TUR 34098 Turkey Details
Novartis Investigative Site Adana 01250 Turkey Details
Novartis Investigative Site Ankara 06500 Turkey Details
Novartis Investigative Site Edirne 22030 Turkey Details
Novartis Investigative Site Hanoi 100000 Vietnam Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field